Online inquiry

IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12552MR)

This product GTTS-WQ12552MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets Canlupfam NGF gene. The antibody can be applied in Osteoarthritis (OA) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Caninized
RefSeq NM_001194950.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 403402
UniProt ID F1PDQ3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12552MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6026MR IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CNTO 1275
GTTS-WQ3724MR IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY 94-9343
GTTS-WQ3259MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ART621
GTTS-WQ11608MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MGD-006
GTTS-WQ2735MR IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG-139
GTTS-WQ7658MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GEN-1029
GTTS-WQ10996MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MCDS0593A
GTTS-WQ2935MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG888
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW